Hence, in vivo and in vitro experiments were designed to investigate the potential regulatory mechanism of CD4+ T cells in the CIK cell population for clinical screening of suitable NSCLC patients for CIK therapy. This evidence concerns the gene CD4 and non-small cell lung carcinoma.